Boundless Bio (BOLD) traded flat 0 % during a 24 hours period ending at 10:17 AM Central Europe on Wednesday 28th. One Boundless Bio stock can currently be bought for about USD 2.41 on popular exchanges. Current supply of Boundless Bio stocks is 23.1 mn. Boundless Bio has a current market capitalization of USD 55.2 mn and approximately USD 219.6 k worth of Boundless Bio was traded on exchanges in the last 24 hours. Since last month end, Boundless Bio has traded -7.66 % down. Simple moving average of last 200 days is at USD 1.89. The highest price of past 52 weeks was recorded at USD 3.16 on 08/24/2026. 52 weeks low was at USD 0.96 on 02/05/2026.
Here is how related stocks have performed in the past 24 hours:
Safe Pro (SPAI) traded up 2.17 % and now trades at USD 3.29. Safe Pro has a market capitalisation of USD 65.6 mn.
Xcf Global (SAFX) traded down -9.55 % and now trades at USD 0.14. Current market capitalisation for Xcf Global is USD 65.1 mn. XCF Global, Inc. filed an amendment to its Schedule 13D on 26 October 2026, disclosing that two reporting persons—EEME Energy SPV I, LLC and individual Majique Ladnier—hold a combined share of roughly 83 percent of the company’s common stock. The amendment notes that these owners acquired their stakes through a combination of promissory‑note conversions, outright purchases and a recent business combination that transferred the entire holding of Southern Energy Renewables to XCF. On the same day, the company issued a definitive proxy statement for a special meeting scheduled for 9 November 2026. The meeting will address a proposal to amend the certificate of incorporation to effect a reverse stock split of the company’s common shares, a step intended to help the company maintain compliance with Nasdaq’s minimum bid‑price rule. The proxy also includes a motion to adjourn the meeting if sufficient votes are not obtained. Separately, an ownership report filed by Langley Chad J., a director, confirms the ownership of a single share of the company’s stock. The filings collectively illustrate XCF’s ongoing efforts to manage share structure and maintain market listing standards.
Citius Oncology (CTOR) traded up 2.52 % and now trades at USD 0.61. Current market capitalisation for Citius Oncology is USD 65.2 mn. Citius Oncology, Inc. filed a current report on 26 October 2026 detailing the progress of its flagship product, LYMPHIR® (denileukin diftitox‑cxdl). The company announced that unit sales to U.S. wholesalers rose by more than 100 percent during the fourth quarter ended September 30, 2026, and that orders from prescribing centers increased modestly. Management noted that the expanded commercial team has broadened national coverage, bringing the company closer to its goal of having LYMPHIR listed on the formularies of 100 priority institutions by year‑end. The filing also included the company’s financial statements and related exhibits, with a reminder that the reported figures are preliminary and unaudited. Citius Oncology remains a Nasdaq‑listed emerging growth company headquartered in Cranford, New Jersey.
Ebr (EBR.AX) traded down -7.41 % and now trades at AUD 0.13. Ebr has a market capitalisation of AUD 94.2 mn.
Nomad Power (NMAD) traded down -2.48 % and now trades at USD 3.94. Nomad Power has a market capitalisation of USD 65.1 mn.